Castlekeep Investment Advisors LLC Acquires Shares of 4,507 Koninklijke Philips (NYSE:PHG)

Castlekeep Investment Advisors LLC bought a new position in Koninklijke Philips (NYSE:PHG) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 4,507 shares of the technology company’s stock, valued at approximately $114,000.

Other large investors have also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new position in shares of Koninklijke Philips during the third quarter valued at approximately $54,000. Farther Finance Advisors LLC increased its stake in Koninklijke Philips by 37.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,150 shares of the technology company’s stock worth $54,000 after purchasing an additional 582 shares during the period. Whipplewood Advisors LLC bought a new stake in shares of Koninklijke Philips during the fourth quarter worth $55,000. Millstone Evans Group LLC purchased a new stake in shares of Koninklijke Philips during the fourth quarter valued at $60,000. Finally, Allworth Financial LP grew its holdings in shares of Koninklijke Philips by 24.9% in the fourth quarter. Allworth Financial LP now owns 3,993 shares of the technology company’s stock worth $105,000 after purchasing an additional 797 shares during the last quarter. 13.67% of the stock is owned by hedge funds and other institutional investors.

Koninklijke Philips Trading Up 0.2 %

PHG opened at $25.64 on Tuesday. The company has a current ratio of 1.23, a quick ratio of 0.74 and a debt-to-equity ratio of 0.59. The firm has a market cap of $24.10 billion, a price-to-earnings ratio of -30.53, a PEG ratio of 0.82 and a beta of 0.81. Koninklijke Philips has a 12 month low of $21.48 and a 12 month high of $32.91. The stock has a fifty day moving average price of $25.02 and a 200-day moving average price of $26.08.

Koninklijke Philips (NYSE:PHG) last issued its quarterly earnings data on Wednesday, February 19th. The technology company reported $0.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.01). Koninklijke Philips had a positive return on equity of 10.85% and a negative net margin of 3.88%. The firm had revenue of $5.38 billion during the quarter, compared to analysts’ expectations of $5.10 billion. As a group, equities research analysts anticipate that Koninklijke Philips will post 1.63 earnings per share for the current fiscal year.

Koninklijke Philips Cuts Dividend

The firm also recently disclosed an annual dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 13th will be issued a dividend of $0.886 per share. The ex-dividend date of this dividend is Tuesday, May 13th. This represents a dividend yield of 2.9%. Koninklijke Philips’s dividend payout ratio is presently -89.29%.

Analysts Set New Price Targets

PHG has been the subject of several research reports. Sanford C. Bernstein raised shares of Koninklijke Philips from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 18th. StockNews.com raised Koninklijke Philips from a “hold” rating to a “buy” rating in a research report on Saturday, March 8th. BNP Paribas raised Koninklijke Philips from a “neutral” rating to an “outperform” rating in a research report on Tuesday, February 25th. Finally, UBS Group upgraded Koninklijke Philips from a “neutral” rating to a “buy” rating in a report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Koninklijke Philips presently has a consensus rating of “Buy”.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.